Thirdly, the proportion of patients with bilateral eye involvement was high: 66.7% of the MOG-ON patients who developed symptoms within 6 weeks after COVID-19 had bilateral eye involvement, while only 9.1% of the other MOG-ON patients had this feature. The gene discussed is MOG; the disease is COVID-19.